Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| BIO-TECHNE CorpTECH · Entity 3479 | Director | October 30, 2025 | November 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,098 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 60,414 · Balance 110,098 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
BIO-TECHNE Corp
Report date October 30, 2025 · Filed November 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,782 |
Reported balance
After 2025-10-30 transaction · row 1
1 source rowRow 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 3,782 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
After 2025-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.46 · Expires 2034-05-01 | Direct | 1,610 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,610 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,511 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000018 · form4.xml · derivative · entry 4 Klimovsky Judith V. · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000018 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V. · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,782 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018028 · form4.xml · derivative · entry 3 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018028 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,142 Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,610 | $0.00 Strike: $73.46 | $0.00 |
DisclosureSEC source: 0001062993-24-009351 · form4.xml · derivative · entry 2 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,610 Underlying: Common Stock · 1,610 shares Expires 2034-05-01 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the grant date or the date of Bio-Techne's annual meeting of shareholders. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009351 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 13:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 60,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000413 · wf-form4_167294187447428.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 10:30 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 35,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024221 · wf-form4_166212902092346.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 14:47 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001628280-22-017339 · wf-form4_165540523301043.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:34 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 566 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000411 · wf-form4_164147965932261.xml · derivative · entry 4 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The RSUs granted on July 1, 2021 vest in full on January 4, 2022. F3 · derivative.expiration_date: The RSUs granted on July 1, 2021 vest in full on January 4, 2022. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:34 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 14,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000411 · wf-form4_164147965932261.xml · derivative · entry 3 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021. F2 · derivative.expiration_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:34 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 566 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000411 · wf-form4_164147965932261.xml · nonDerivative · entry 2 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:34 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 14,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000411 · wf-form4_164147965932261.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:31 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045707 · doc4.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566 Underlying: Common Stock · 566 shares Expires 2022-01-04 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 15, 2021 Filed Jul 7, 2021 20:28 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-045945 · doc4.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-14 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 14,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000099 · wf-form4_160988993769483.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,036 Underlying: Common Stock · 14,036 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs will vest in full upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs will vest in full upon the one year anniversary of the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 16:50 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001628280-20-009549 · wf-form4_159234061503655.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001358403-19-000097 · wf-form4_156054272824655.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 21:23 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001209191-18-063791 · doc4.xml · derivative · entry 2 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-12-19 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments until the date of the Company's 2019 annual meeting of stockholders. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 21:23 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001209191-18-063791 · doc4.xml · derivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-12-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments over a three-year period beginning from December 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.